Myelodysplastic (MDS) syndrome is a type of bone marrow disorder, where bone marrow is unable to produce healthy and mature blood cells. The immature blood cells called as blasts, get stored in the bone marrow and blood and obstruct the natural function of the hematological system which results in depletion of healthy red blood cells, platelets, and white blood cells. Myelodysplastic syndrome is usually seen in geriatric population and more often in older men than women. This syndrome is characterized by certain chromosomal mutations in Janus Kinase gene which include deletion of q arm in one or more chromosomes and complete deletion of chromosome 5 or 7 and an extra copy of chromosome 8.
Scope of the Report:
This report focuses on the Myelodysplastic Syndrome (MDS) Treatment in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
According to the American Cancer Society, the incidence rate for myelodysplastic syndrome is 13,000 new cases each year which happens at a rate of 4.8 cases per 100,000 people. This trend is heavily affected or rather influenced by the average age of the population which, according to the World Health Organization (WHO), is increasing and is expected to double from 12% to 22% between 2015 and 2050.
The worldwide market for Myelodysplastic Syndrome (MDS) Treatment is expected to grow at a CAGR of roughly 12.8% over the next five years, will reach 4560 million US$ in 2023, from 2210 million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
- Novartis AG
- Celgene Corporation
- Otsuka Pharmaceutical Co., Ltd
- Sandoz Inc
- Dr Reddys Laboratories Limited
- Pharmascience Inc
- Accord Healthcare Ltd
- Mylan N.V.
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Azacitidine
- Lenalidomide
- Decitabine
- Deferasirox
Market Segment by Applications, can be divided into
- Refractory cytopenia with unilineage dysplasia
- Refractory anemia with ringed sideroblasts
- Others
There are 15 Chapters to deeply display the global Myelodysplastic Syndrome (MDS) Treatment market.
Chapter 1, to describe Myelodysplastic Syndrome (MDS) Treatment Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Myelodysplastic Syndrome (MDS) Treatment, with sales, revenue, and price of Myelodysplastic Syndrome (MDS) Treatment, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Myelodysplastic Syndrome (MDS) Treatment, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Myelodysplastic Syndrome (MDS) Treatment market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Myelodysplastic Syndrome (MDS) Treatment sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Myelodysplastic Syndrome (MDS) Treatment Market 2018, Forecast to 2023
Table of Contents
1 Market Overview
1.1 Myelodysplastic Syndrome (MDS) Treatment Introduction
1.2 Market Analysis by Type
1.2.1 Azacitidine
1.2.2 Lenalidomide
1.2.3 Decitabine
1.2.4 Deferasirox
1.3 Market Analysis by Applications
1.3.1 Refractory cytopenia with unilineage dysplasia
1.3.2 Refractory anemia with ringed sideroblasts
1.3.3 Others
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Novartis AG
2.1.1 Business Overview
2.1.1.1 Novartis AG Description
2.1.1.2 Novartis AG Headquarter, Main Business and Finance Overview
2.1.2 Novartis AG Myelodysplastic Syndrome (MDS) Treatment Product Introduction
2.1.2.1 Myelodysplastic Syndrome (MDS) Treatment Production Bases, Sales Regions and Major Competitors
2.1.2.2 Myelodysplastic Syndrome (MDS) Treatment Product Information
2.1.3 Novartis AG Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.1.3.1 Novartis AG Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.1.3.2 Global Novartis AG Myelodysplastic Syndrome (MDS) Treatment Market Share in 2017
2.2 Celgene Corporation
2.2.1 Business Overview
2.2.1.1 Celgene Corporation Description
2.2.1.2 Celgene Corporation Headquarter, Main Business and Finance Overview
2.2.2 Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Product Introduction
2.2.2.1 Myelodysplastic Syndrome (MDS) Treatment Production Bases, Sales Regions and Major Competitors
2.2.2.2 Myelodysplastic Syndrome (MDS) Treatment Product Information
2.2.3 Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2.3.1 Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2.3.2 Global Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Market Share in 2017
2.3 Otsuka Pharmaceutical Co., Ltd
2.3.1 Business Overview
2.3.1.1 Otsuka Pharmaceutical Co., Ltd Description
2.3.1.2 Otsuka Pharmaceutical Co., Ltd Headquarter, Main Business and Finance Overview
2.3.2 Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Product Introduction
2.3.2.1 Myelodysplastic Syndrome (MDS) Treatment Production Bases, Sales Regions and Major Competitors
2.3.2.2 Myelodysplastic Syndrome (MDS) Treatment Product Information
2.3.3 Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3.3.1 Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3.3.2 Global Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Market Share in 2017
2.4 Sandoz Inc
2.4.1 Business Overview
2.4.1.1 Sandoz Inc Description
2.4.1.2 Sandoz Inc Headquarter, Main Business and Finance Overview
2.4.2 Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Product Introduction
2.4.2.1 Myelodysplastic Syndrome (MDS) Treatment Production Bases, Sales Regions and Major Competitors
2.4.2.2 Myelodysplastic Syndrome (MDS) Treatment Product Information
2.4.3 Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4.3.1 Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4.3.2 Global Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Market Share in 2017
2.5 Dr Reddys Laboratories Limited
2.5.1 Business Overview
2.5.1.1 Dr Reddys Laboratories Limited Description
2.5.1.2 Dr Reddys Laboratories Limited Headquarter, Main Business and Finance Overview
2.5.2 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Product Introduction
2.5.2.1 Myelodysplastic Syndrome (MDS) Treatment Production Bases, Sales Regions and Major Competitors
2.5.2.2 Myelodysplastic Syndrome (MDS) Treatment Product Information
2.5.3 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5.3.1 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5.3.2 Global Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Market Share in 2017
2.6 Pharmascience Inc
2.6.1 Business Overview
2.6.1.1 Pharmascience Inc Description
2.6.1.2 Pharmascience Inc Headquarter, Main Business and Finance Overview
2.6.2 Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Product Introduction
2.6.2.1 Myelodysplastic Syndrome (MDS) Treatment Production Bases, Sales Regions and Major Competitors
2.6.2.2 Myelodysplastic Syndrome (MDS) Treatment Product Information
2.6.3 Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6.3.1 Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6.3.2 Global Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Market Share in 2017
2.7 Accord Healthcare Ltd
2.7.1 Business Overview
2.7.1.1 Accord Healthcare Ltd Description
2.7.1.2 Accord Healthcare Ltd Headquarter, Main Business and Finance Overview
2.7.2 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Product Introduction
2.7.2.1 Myelodysplastic Syndrome (MDS) Treatment Production Bases, Sales Regions and Major Competitors
2.7.2.2 Myelodysplastic Syndrome (MDS) Treatment Product Information
2.7.3 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7.3.1 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7.3.2 Global Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Market Share in 2017
2.8 Mylan N.V.
2.8.1 Business Overview
2.8.1.1 Mylan N.V. Description
2.8.1.2 Mylan N.V. Headquarter, Main Business and Finance Overview
2.8.2 Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Product Introduction
2.8.2.1 Myelodysplastic Syndrome (MDS) Treatment Production Bases, Sales Regions and Major Competitors
2.8.2.2 Myelodysplastic Syndrome (MDS) Treatment Product Information
2.8.3 Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8.3.1 Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8.3.2 Global Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Market Share in 2017
3 Global Myelodysplastic Syndrome (MDS) Treatment Market Competition, by Manufacturer
3.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue and Market Share by Manufacturer (2016-2017)
3.3 Global Myelodysplastic Syndrome (MDS) Treatment Price by Manufacturer (2016-2017)
3.4 Market Concentration Rate
3.4.1 Top 3 Myelodysplastic Syndrome (MDS) Treatment Manufacturer Market Share in 2017
3.4.2 Top 5 Myelodysplastic Syndrome (MDS) Treatment Manufacturer Market Share in 2017
3.5 Market Competition Trend
4 Global Myelodysplastic Syndrome (MDS) Treatment Market Analysis by Regions
4.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Regions
4.1.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales by Regions (2013-2018)
4.1.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Regions (2013-2018)
4.2 North America Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Growth Rate (2013-2018)
4.3 Europe Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Growth Rate (2013-2018)
4.5 South America Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Growth Rate (2013-2018)
5 North America Myelodysplastic Syndrome (MDS) Treatment by Countries, Type, Application and Manufacturers
5.1 North America Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Countries
5.1.1 North America Myelodysplastic Syndrome (MDS) Treatment Sales by Countries (2013-2018)
5.1.2 North America Myelodysplastic Syndrome (MDS) Treatment Revenue by Countries (2013-2018)
5.1.3 United States Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)
5.1.4 Canada Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)
5.1.5 Mexico Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)
5.2 North America Myelodysplastic Syndrome (MDS) Treatment Sales and Revenue (Value) by Manufacturers (2016-2017)
5.2.1 North America Myelodysplastic Syndrome (MDS) Treatment Sales by Manufacturers (2016-2017)
5.2.2 North America Myelodysplastic Syndrome (MDS) Treatment Revenue by Manufacturers (2016-2017)
5.3 North America Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Type (2013-2018)
5.3.1 North America Myelodysplastic Syndrome (MDS) Treatment Sales and Sales Share by Type (2013-2018)
5.3.2 North America Myelodysplastic Syndrome (MDS) Treatment Revenue and Revenue Share by Type (2013-2018)
5.4 North America Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Application (2013-2018)
5.4.1 North America Myelodysplastic Syndrome (MDS) Treatment Sales and Sales Share by Application (2013-2018)
5.4.2 North America Myelodysplastic Syndrome (MDS) Treatment Revenue and Revenue Share by Application (2013-2018)
6 Europe Myelodysplastic Syndrome (MDS) Treatment by Countries, Type, Application and Manufacturers
6.1 Europe Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Countries
6.1.1 Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Countries (2013-2018)
6.1.2 Europe Myelodysplastic Syndrome (MDS) Treatment Revenue by Countries (2013-2018)
6.1.3 Germany Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)
6.1.4 UK Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)
6.1.5 France Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)
6.1.6 Russia Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)
6.1.7 Italy Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)
6.2 Europe Myelodysplastic Syndrome (MDS) Treatment Sales and Revenue (Value) by Manufacturers (2016-2017)
6.2.1 Europe Myelodysplastic Syndrome (MDS) Treatment Sales by Manufacturers (2016-2017)
6.2.2 Europe Myelodysplastic Syndrome (MDS) Treatment Revenue by Manufacturers (2016-2017)
6.3 Europe Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Type (2013-2018)
6.3.1 Europe Myelodysplastic Syndrome (MDS) Treatment Sales and Sales Share by Type (2013-2018)
6.3.2 Europe Myelodysplastic Syndrome (MDS) Treatment Revenue and Revenue Share by Type (2013-2018)
6.4 Europe Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Application (2013-2018)
6.4.1 Europe Myelodysplastic Syndrome (MDS) Treatment Sales and Sales Share by Application (2013-2018)
6.4.2 Europe Myelodysplastic Syndrome (MDS) Treatment Revenue and Revenue Share by Application (2013-2018)
7 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment by Countries, Type, Application and Manufacturers
7.1 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales by Countries (2013-2018)
7.1.2 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue by Countries (2013-2018)
7.1.3 China Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)
7.1.4 Japan Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)
7.1.5 Korea Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)
7.1.6 India Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)
7.1.7 Southeast Asia Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)
7.2 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales and Revenue (Value) by Manufacturers (2016-2017)
7.2.1 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales by Manufacturers (2016-2017)
7.2.2 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue by Manufacturers (2016-2017)
7.3 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Type (2013-2018)
7.3.1 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales and Sales Share by Type (2013-2018)
7.3.2 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue and Revenue Share by Type (2013-2018)
7.4 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Application (2013-2018)
7.4.1 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Sales and Sales Share by Application (2013-2018)
7.4.2 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Revenue and Revenue Share by Application (2013-2018)
8 South America Myelodysplastic Syndrome (MDS) Treatment by Countries, Type, Application and Manufacturers
8.1 South America Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Countries
8.1.1 South America Myelodysplastic Syndrome (MDS) Treatment Sales by Countries (2013-2018)
8.1.2 South America Myelodysplastic Syndrome (MDS) Treatment Revenue by Countries (2013-2018)
8.1.3 Brazil Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)
8.1.4 Argentina Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)
8.1.5 Colombia Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)
8.2 South America Myelodysplastic Syndrome (MDS) Treatment Sales and Revenue (Value) by Manufacturers (2016-2017)
8.2.1 South America Myelodysplastic Syndrome (MDS) Treatment Sales by Manufacturers (2016-2017)
8.2.2 South America Myelodysplastic Syndrome (MDS) Treatment Revenue by Manufacturers (2016-2017)
8.3 South America Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Type (2013-2018)
8.3.1 South America Myelodysplastic Syndrome (MDS) Treatment Sales and Sales Share by Type (2013-2018)
8.3.2 South America Myelodysplastic Syndrome (MDS) Treatment Revenue and Revenue Share by Type (2013-2018)
8.4 South America Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Application (2013-2018)
8.4.1 South America Myelodysplastic Syndrome (MDS) Treatment Sales and Sales Share by Application (2013-2018)
8.4.2 South America Myelodysplastic Syndrome (MDS) Treatment Revenue and Revenue Share by Application (2013-2018)
9 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment by Countries, Type, Application and Manufacturers
9.1 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Countries (2013-2018)
9.1.2 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Revenue by Countries (2013-2018)
9.1.3 Saudi Arabia Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)
9.1.4 UAE Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)
9.1.5 Egypt Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)
9.1.6 Nigeria Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)
9.1.7 South Africa Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)
9.2 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales and Revenue (Value) by Manufacturers (2016-2017)
9.2.1 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales by Manufacturers (2016-2017)
9.2.2 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Revenue by Manufacturers (2016-2017)
9.3 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Type (2013-2018)
9.3.1 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales and Sales Share by Type (2013-2018)
9.3.1 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Revenue and Revenue Share by Type (2013-2018)
9.4 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Application (2013-2018)
9.4.1 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Sales and Sales Share by Application (2013-2018)
9.4.2 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Revenue and Revenue Share by Application (2013-2018)
10 Global Myelodysplastic Syndrome (MDS) Treatment Market Segment by Type
10.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales and Market Share by Type (2013-2018)
10.1.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue and Market Share by Type (2013-2018)
10.2 Azacitidine Sales Growth and Price
10.2.1 Global Azacitidine Sales Growth (2013-2018)
10.2.2 Global Azacitidine Price (2013-2018)
10.3 Lenalidomide Sales Growth and Price
10.3.1 Global Lenalidomide Sales Growth (2013-2018)
10.3.2 Global Lenalidomide Price (2013-2018)
10.4 Decitabine Sales Growth and Price
10.4.1 Global Decitabine Sales Growth (2013-2018)
10.4.2 Global Decitabine Price (2013-2018)
10.5 Deferasirox Sales Growth and Price
10.5.1 Global Deferasirox Sales Growth (2013-2018)
10.5.2 Global Deferasirox Price (2013-2018)
11 Global Myelodysplastic Syndrome (MDS) Treatment Market Segment by Application
11.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Application (2013-2018)
11.2 Refractory cytopenia with unilineage dysplasia Sales Growth (2013-2018)
11.3 Refractory anemia with ringed sideroblasts Sales Growth (2013-2018)
11.4 Others Sales Growth (2013-2018)
12 Myelodysplastic Syndrome (MDS) Treatment Market Forecast (2018-2023)
12.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales, Revenue and Growth Rate (2018-2023)
12.2 Myelodysplastic Syndrome (MDS) Treatment Market Forecast by Regions (2018-2023)
12.2.1 North America Myelodysplastic Syndrome (MDS) Treatment Market Forecast (2018-2023)
12.2.2 Europe Myelodysplastic Syndrome (MDS) Treatment Market Forecast (2018-2023)
12.2.3 Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Market Forecast (2018-2023)
12.2.4 South America Myelodysplastic Syndrome (MDS) Treatment Market Forecast (2018-2023)
12.2.5 Middle East and Africa Myelodysplastic Syndrome (MDS) Treatment Market Forecast (2018-2023)
12.3 Myelodysplastic Syndrome (MDS) Treatment Market Forecast by Type (2018-2023)
12.3.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales Forecast by Type (2018-2023)
12.3.2 Global Myelodysplastic Syndrome (MDS) Treatment Market Share Forecast by Type (2018-2023)
12.4 Myelodysplastic Syndrome (MDS) Treatment Market Forecast by Application (2018-2023)
12.4.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales Forecast by Application (2018-2023)
12.4.2 Global Myelodysplastic Syndrome (MDS) Treatment Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Myelodysplastic Syndrome (MDS) Treatment Picture
Table Product Specifications of Myelodysplastic Syndrome (MDS) Treatment
Figure Global Myelodysplastic Syndrome (MDS) Treatment CAGR (%), Y-o-Y Growth (&) and Market Size, 2013-2023 (USD Million)
Figure Global Myelodysplastic Syndrome (MDS) Treatment CAGR (%), Y-o-Y Growth (&) and Market Size, 2013-2023 (Sales)
Figure Global Sales Market Share of Myelodysplastic Syndrome (MDS) Treatment by Types in 2017
Figure Azacitidine Picture
Table Major Manufacturers of Azacitidine
Figure Lenalidomide Picture
Table Major Manufacturers of Lenalidomide
Figure Decitabine Picture
Table Major Manufacturers of Decitabine
Figure Deferasirox Picture
Table Major Manufacturers of Deferasirox
Figure Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Applications in 2017
Figure Refractory cytopenia with unilineage dysplasia Picture
Figure Refractory anemia with ringed sideroblasts Picture
Figure Others Picture
Figure United States Myelodysplastic Syndrome (MDS) Treatment Revenue (Value) and Growth Rate (2013-2023)
Figure Canada Myelodysplastic Syndrome (MDS) Treatment Revenue (Value) and Growth Rate (2013-2023)
Figure Mexico Myelodysplastic Syndrome (MDS) Treatment Revenue (Value) and Growth Rate (2013-2023)
Figure Germany Myelodysplastic Syndrome (MDS) Treatment Revenue (Value) and Growth Rate (2013-2023)
Figure France Myelodysplastic Syndrome (MDS) Treatment Revenue (Value) and Growth Rate (2013-2023)
Figure UK Myelodysplastic Syndrome (MDS) Treatment Revenue (Value) and Growth Rate (2013-2023)
Figure Russia Myelodysplastic Syndrome (MDS) Treatment Revenue (Value) and Growth Rate (2013-2023)
Figure Italy Myelodysplastic Syndrome (MDS) Treatment Revenue (Value) and Growth Rate (2013-2023)
Figure China Myelodysplastic Syndrome (MDS) Treatment Revenue (Value) and Growth Rate (2013-2023)
Figure Japan Myelodysplastic Syndrome (MDS) Treatment Revenue (Value) and Growth Rate (2013-2023)
Figure Korea Myelodysplastic Syndrome (MDS) Treatment Revenue (Value) and Growth Rate (2013-2023)
Figure India Myelodysplastic Syndrome (MDS) Treatment Revenue (Value) and Growth Rate (2013-2023)
Figure Southeast Asia Myelodysplastic Syndrome (MDS) Treatment Revenue (Value) and Growth Rate (2013-2023)
Figure Brazil Myelodysplastic Syndrome (MDS) Treatment Revenue (Value) and Growth Rate (2013-2023)
Figure Egypt Myelodysplastic Syndrome (MDS) Treatment Revenue (Value) and Growth Rate (2013-2023)
Figure Saudi Arabia Myelodysplastic Syndrome (MDS) Treatment Revenue (Value) and Growth Rate (2013-2023)
Figure South Africa Myelodysplastic Syndrome (MDS) Treatment Revenue (Value) and Growth Rate (2013-2023)
Figure Nigeria Myelodysplastic Syndrome (MDS) Treatment Revenue (Value) and Growth Rate (2013-2023)
Table Novartis AG Headquarter, Established, Main Business and Finance Overview (2017)
Table Novartis AG Myelodysplastic Syndrome (MDS) Treatment Production Bases, Sales Regions and Major Competitors
Table Novartis AG Myelodysplastic Syndrome (MDS) Treatment Product
Table Novartis AG Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Novartis AG Myelodysplastic Syndrome (MDS) Treatment Sales Market Share in 2017
Figure Global Novartis AG Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share in 2017
Table Celgene Corporation Headquarter, Established, Main Business and Finance Overview (2017)
Table Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Production Bases, Sales Regions and Major Competitors
Table Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Product
Table Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Sales Market Share in 2017
Figure Global Celgene Corporation Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share in 2017
Table Otsuka Pharmaceutical Co., Ltd Headquarter, Established, Main Business and Finance Overview (2017)
Table Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Production Bases, Sales Regions and Major Competitors
Table Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Product
Table Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Sales Market Share in 2017
Figure Global Otsuka Pharmaceutical Co., Ltd Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share in 2017
Table Sandoz Inc Headquarter, Established, Main Business and Finance Overview (2017)
Table Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Production Bases, Sales Regions and Major Competitors
Table Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Product
Table Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Sales Market Share in 2017
Figure Global Sandoz Inc Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share in 2017
Table Dr Reddys Laboratories Limited Headquarter, Established, Main Business and Finance Overview (2017)
Table Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Production Bases, Sales Regions and Major Competitors
Table Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Product
Table Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Sales Market Share in 2017
Figure Global Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share in 2017
Table Pharmascience Inc Headquarter, Established, Main Business and Finance Overview (2017)
Table Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Production Bases, Sales Regions and Major Competitors
Table Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Product
Table Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Sales Market Share in 2017
Figure Global Pharmascience Inc Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share in 2017
Table Accord Healthcare Ltd Headquarter, Established, Main Business and Finance Overview (2017)
Table Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Production Bases, Sales Regions and Major Competitors
Table Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Product
Table Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Sales Market Share in 2017
Figure Global Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share in 2017
Table Mylan N.V. Headquarter, Established, Main Business and Finance Overview (2017)
Table Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Production Bases, Sales Regions and Major Competitors
Table Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Product
Table Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
Figure Global Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Sales Market Share in 2017
Figure Global Mylan N.V. Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share in 2017
Table Global Myelodysplastic Syndrome (MDS) Treatment Sales by Manufacturer (2016-2017)
Figure Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Manufacturer in 2016
Figure Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Manufacturer in 2017
Table Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Manufacturer (2016-2017)
Figure Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Manufacturer in 2016
Figure Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Manufacturer in 2017
Table Global Myelodysplastic Syndrome (MDS) Treatment Price by Manufacturer (2016-2017)
Figure Top 3 Myelodysplastic Syndrome (MDS) Treatment Manufacturer (Revenue) Market Share in 2017
Figure Top 6 Myelodysplastic Syndrome (MDS) Treatment Manufacturer (Revenue) Market Share in 2017
Figure Global Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)
Figure Global Myelodysplastic Syndrome (MDS) Treatment Revenue and Growth Rate (2013-2018)
Table Global Myelodysplastic Syndrome (MDS) Treatment Sales by Regions (2013-2018)
Table Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Regions (2013-2018)
Table Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Regions (2013-2018)
Figure Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Regions in 2013
Figure Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Regions in 2017
Figure North America Myelodysplastic Syndrome (MDS) Treatment Sales and Growth Rate (2013-2018)
Figure
Global Antioxidant Vitamins Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 100
The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
Global Clavulanate Potassium Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 86
The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030.
North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
Global Amoxicillin Sodium Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 84
The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030.
North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
Global Melatonin Supplements Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 106
The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 93
The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
Global Sleeping Pills Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 94
The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
Global Zinc Oral Drops Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 85
The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
Global Zinc Drops Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 85
The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
Global Anti-Infectives Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 78
The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
